TET2基因突变在髓系肿瘤中的研究进展

doi:10.3881/j.issn.1000-503X.2016.05.017

Acta Academiae Medicinae Sinica

Acta Academiae Medicinae Sinica ›› 2016, Vol. 38 ›› Issue (5): 583-588.doi: 10.3881/j.issn.1000-503X.2016.05.017

• Orginal Article • Previous Articles Next Articles

Research Advances in the Mutation of TET2 Gene in Myeloid Maligancies

Rong LI, Ming-jiang XU, Feng-chun YANG, Yuan ZHOU()

State Key Laboratory of Experimental Hematology,Institute of Hematology and Blood Disease Hospital,CAMS and PUMC,Tianjin 300020,China

Received:2015-09-08 Online:2016-10-20 Published:2016-10-10
Supported by:
Supported by the National Nature Sciences Foundation of China(81328003)and the Major Program of Applied Basic Research Foundation of Tianjin (13JCZDJC31200)

Abstract

Abstract:

TET2 gene is a member of TET oncogene family. It has been reported as a tumor suppressor gene with important roles in myelopiesis. Recent studies have shown that TET2 protein takes part in demethylation by converting 5-methylcytosine (5-mc) into 5-hydroxymethylcytosine (5-hmc). Somatic TET2 inactivation leads to abnormal myelopiesis and myeloid malignancies. In this review,the structure and function of TET2 and the relationship between TET gene mutation and myeloid malignancies are summarized.

Key words: TET2, mutation, myeloid malignancies

CLC Number:

Rong LI, Ming-jiang XU, Feng-chun YANG, Yuan ZHOU. Research Advances in the Mutation of TET2 Gene in Myeloid Maligancies[J].Acta Academiae Medicinae Sinica, 2016, 38(5): 583-588.

References 40

[1]	Mohr F,Dohner K,Buske C,et al.TET genes: new players in DNA demethylation and important determinants for stemness[J]. Exp Hematol,2011,39(3):272-281.
[2]	Hu L,Li Z,Cheng J,et al.Crystal structure of TET2-DNA complex: insight into TET-mediated 5 mC oxidation[J]. Cell,2013,155(7):1545-1555.
[3]	Ko M,An J,Bandukwala HS,et al.Modulation of TET2 expression and 5-methylcytosine oxidation by the CXXC domain protein IDAX[J]. Nature,2013,497(7447):122-126.
[4]	Hamidi T,Singh AK,Chen T.Genetic alterations of DNA methylation machinery in human diseases[J]. Epigenomics,2015,7(2):247-265.
[5]	Yin R,Mao SQ,Zhao B,et al.Ascorbic acid enhances Tet-mediated 5-methylcytosine oxidation and promotes DNA demethylation in mammals[J]. J Am Chem Soc,2013,135(28):10396-10403.
[6]	Li Z,Cai X,Cai CL,et al.Deletion of Tet2 in mice leads to dysregulated hematopoietic stem cells and subsequent development of myeloid malignancies[J]. Blood,2011,118(17):4509-4518.
[7]	Koh KP,Yabuuchi A,Rao S,et al.Tet1 and Tet2 regulate 5-hydroxymethylcytosine production and cell lineage specification in mouse embryonic stem cells[J]. Cell Stem Cell,2011,8(2):200-213.
[8]	Song SJ,Ito K,Ala U,et al.The oncogenic microRNA miR-22 targets the TET2 tumor suppressor to promote hematopoietic stem cell self-renewal and transformation[J]. Cell Stem Cell,2013,13(1):87-101.
[9]	Cheng J,Guo S,Chen S,et al.An extensive network of TET2-targeting MicroRNAs regulates malignant hematopoiesis[J]. Cell Rep,2013,5(2):471-481.
[10]	Pendino F,Nguyen E,Jonassen I,et al.Functional involvement of RINF,retinoid-inducible nuclear factor (CXXC5),in normal and tumoral human myelopoiesis[J]. Blood,2009,113(14): 3172-3181.
[11]	Wang Y,Xiao M,Chen X,et al.WT1 recruits TET2 to regulate its target gene expression and suppress leukemia cell proliferation[J]. Mol Cell,2015,57(4):662-673.
[12]	Rampal R,Alkalin A,Madzo J,et al.DNA hydroxymethylation profiling reveals that WT1 mutations result in loss of TET2 function in acute myeloid leukemia[J]. Cell Rep,2014,9(5):1841-1855.
[13]	Langemeijer SM,Aslanyan MG,Jansen JH.TET proteins in malignant hematopoiesis[J]. Cell Cycle,2009,8(24):4044-4048.
[14]	Delhommeau F,Dupont S,James C,et al. TET2 is a novel tumor suppressor gene inactivated in myeloproliferative neoplasms: identification of a pre-JAK2 V617F event[J]. Blood,2008,112(11): 1ba-3.
[15]	Delhommeau F,Dupont S,Della Valle V,et al.Mutation in TET2 in myeloid cancers[J]. N Engl J Med,2009,360(22):2289-2301.
[16]	Tefferi A,Levine RL,Lim KH,et al.Frequent TET2 mutations in systemic mastocytosis: clinical,KITD816V and FIP1L1-PDGFRA correlates[J]. Leukemia,2009,23(5):900-904.
[17]	Abdel-Wahab O,Mullally A,Hedvat C,et al.Genetic characterization of TET1,TET2,and TET3 alterations in myeloid malignancies[J]. Blood,2009,114(1):144-147.
[18]	Couronne L,Lippert E,Andrieux J,et al.Analyses of TET2 mutations in post-myeloproliferative neoplasm acute myeloid leukemias[J]. Leukemia,2010,24(1):201-203.
[19]	Tefferi A,Pardanani A,Lim KH,et al.TET2 mutations and their clinical correlates in polycythemia vera,essential thrombocythemia and myelofibrosis[J]. Leukemia,2009,23(5): 905-911.
[20]	Tefferi A,Lim KH,Abdel-Wahab O,et al.Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML,MDS,MDS/MPN and AML[J]. Leukemia,2009,23(7): 1343-1345.
[21]	Abdel-Wahab O,Levine RL.Genetics of the myeloproliferative neoplasms[J].Curr Opin Hematol,2011,18(2):117-123.
[22]	Tefferi A,Vardiman JW.Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms[J]. Leukemia,2008,22(1):14-22.
[23]	Nangalia J,Massie CE,Baxter EJ,et al.Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2[J]. N Engl J Med,2013,369(25):2391-2405.
[24]	Ortmann CA,Kent DG,Nangalia J,et al.Effect of mutation order on myeloproliferative neoplasms[J]. N Engl J Med,2015,372(7):601-612.
[25]	Franz X,Schaub RL,Sai Li.Clonal analysis of TET2 and JAK2 mutations suggests that TET2 can be a late event in the progression of myeloproliferative neoplasms[J]. Blood,2010,115(10):2003-2007.
[26]	Chen E,Schneider RK,Breyfogle LJ,et al.Distinct effects of concomitant Jak2V617F expression and Tet2 loss in mice promote disease progression in myeloproliferative neoplasms[J]. Blood,2015,125(2):327-335.
[27]	Kameda T,Shide K,Yamaji T,et al.Loss of TET2 has dual roles in murine myeloproliferative neoplasms: disease sustainer and disease accelerator[J]. Blood,2015,125(2):304-315.
[28]	Langemeijer SM,Kuiper RP,Berends M,et al.Acquired mutations in TET2 are common in myelodysplastic syndromes[J]. Nat Genet,2009,41(7):838-842.
[29]	Kosmider O,Gelsi-Boyer V,Cheok M,et al.TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs)[J]. Blood,2009,114(15):3285-3291.
[30]	Smith AE,Mohamedali AM,Kulasekararaj A,et al.Next-generation sequencing of the TET2 gene in 355 MDS and CMML patients reveals low-abundance mutant clones with early origins,but indicates no definite prognostic value[J]. Blood,2010,116(19):3923-3932.
[31]	Woods BA,Levine RL.The role of mutations in epigenetic regulators in myeloid malignancies[J]. Immunol Rev,2015,263(1):22-35.
[32]	Shih AH,Abdel-Wahab O,Patel JP,et al.The role of mutations in epigenetic regulators in myeloid malignancies[J]. Nat Rev Cancer,2012,12(9):599-612.
[33]	Weissmann S,Alpermann T,Grossmann V,et al.Landscape of TET2 mutations in acute myeloid leukemia[J]. Leukemia,2012,26(5):934-942.
[34]	Busque L,Gilliland DG.Clonal evolution in acute myeloid leukemia[J]. Blood. 1993,82(2):337-342.
[35]	Moran-Crusio K,Reavie L,Shih A,et al.Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation[J]. Cancer Cell,2011,20(1):11-24.
[36]	Friedman AD.Cell cycle and developmental control of hematopoiesis by Runx1[J]. J Cell Physiol,2009,219(3):520-524.
[37]	Ko M,Huang Y,Jankowska AM,et al.Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2[J]. Nature,2010,468(7325):839-843.
[38]	Holmfeldt L,Mullighan CG.The role of TET2 in hematologic neoplasms[J]. Cancer Cell,2011,20(1): 1-2.
[39]	Yamazaki J,Taby R,Vasanthakumar A,et al.Effects of TET2 mutations on DNA methylation in chronic myelomonocytic leukemia[J]. Epigenetics,2012,7(2):201-207.
[40]	Solary E,Bernard OA,Tefferi A,et al.The Ten-Eleven Translocation-2 (TET2) gene in hematopoiesis and hematopoietic diseases[J]. Leukemia,2014,28(3):485-496.

Acta Academiae Medicinae Sinica

Home

About Journal

Current Issue

Archive

Search

Contact Us

中文

Research Advances in the Mutation of TET2 Gene in Myeloid Maligancies

RichHTML

PDF (PC)

Like

Knowledge

Abstract

Cite this article

share this article

References 40

Related Articles 15

Metrics

Recommended 10

[1]	Yaru QUAN, Zhen CHEN, Ping QIU, Xiaoyu CUI, Changgui LI, Liyong YUAN. Sequence Analysis and Comparison of the Key Genes of Domestic Live Attenuated Varicella Vaccine [J]. Acta Academiae Medicinae Sinica, 2017, 39(5): 637-642.
[2]	Qi MENG, Xinxin CAO, Jian LI. Significances of MYD88^L265P and CXCR4^WHIM Mutations in Waldenstrom Macroglobulinemia [J]. Acta Academiae Medicinae Sinica, 2017, 39(4): 578-582.
[3]	Ruiqi ZHUGE, Rong ZHOU, Xinhai NI. Progress in Molecular Genetic Study of Mitochondrial Cardiomyopathy [J]. Acta Academiae Medicinae Sinica, 2017, 39(3): 438-444.
[4]	Miao-zhu LI, Jian-zhen LIN, Hai-tao ZHAO. Circulating Tumor DNA in Cancer Management [J]. Acta Academiae Medicinae Sinica, 2016, 38(5): 594-600.
[5]	Yi XING, Ming-feng ZHAO. Colony Stimulating Factor 3 Mutations and Myeloid Malignancies [J]. Acta Academiae Medicinae Sinica, 2016, 38(1): 103-107.
[6]	Yan-hong LI, Ying LIU, Lan HUANG, Yan-feng XU, Hua ZHU, Tao LI, Wei DENG, Chuan QIN. Dynamic Changes of the Quantitative Distribution,Apoptosis and Proliferation of T and B Cells in the Skin of KM Mutant Mice [J]. Acta Academiae Medicinae Sinica, 2015, 37(5): 489-495.
[7]	YANG Xue, LIANG Zhi-yong, MENG Chao, LIANG Jun, YU Zhuang, LIN Yan-song. Invasiveness of Papillary Thyroid Microcarcinoma with BRAF Mutation [J]. Acta Academiae Medicinae Sinica, 2013, 35(4): 398-403.
[8]	MENG Chao, GAO Jie, LIANG Jun, LIANG Zhi-yong, LIN Yan-song. Invasive Properties of Papillary Thyroid Cancer with Concurrent BRAF^V600E Mutationand Rearranged during Transfection Proto-oncogene Protein Expression [J]. Acta Academiae Medicinae Sinica, 2013, 35(1): 64-68.
[9]	YAO Yong, DAI Cong-Xin, WANG Ren-Zhi. Advances in Pathogenesis of Pituitary Adenomas [J]. Acta Academiae Medicinae Sinica, 2011, 33(2): 127-131.
[10]	ZHANG Ju-Hong, LI Nan-Fang, YAN Zhi-Tao, YAO Xiao-Guang, WANG Hong-Mei, ZHANG De-Lian, WANG Xin-Ling. Detection of Genetic Variations of Regulator of G-protein Signaling 2 in Hypertensives by Sequencing [J]. Acta Academiae Medicinae Sinica, 2011, 33(2): 200-204.
[11]	WANG Meng-zhao;ZHANG Xiao-tong;ZHANG Xin-yong;ZHANG Li;ZHONG Wei;XU Li-yan;LI Long-yun. Efficacy and Safety of Erlotinib as Monotherapy for Advanced Non-small Cell Lung Cancer [J]. Acta Academiae Medicinae Sinica, 2010, 32(2): 151-156.
[12]	LI Jing-nan;LI Xiao, ;QIAN Jia-ming;LU Xin-qing;YANG Hong. Effects of K-ras Gene Mutation on Colon Cancer Cell Line Caco-2 Metastasis by Regulating E-cadherin/β-catenin/p120 Protein Complex Formation and RhoA Protein Activity [J]. Acta Academiae Medicinae Sinica, 2010, 32(1): 46-50.
[13]	ZHAO Xin;TANG Ke-jing;TIAN Zheng; CHEN Li-ping; MI Ying-chang;WANG Jian-xiang. FLT3 Mutation in Patients with Acute Lymphoblastic Leukemia and Its Clinical Significance [J]. Acta Academiae Medicinae Sinica, 2009, 31(5): 522-526.
[14]	QU Yu-jin, SONG Fang, JIN Yu-wei, WANG Hong. Mutation Analysis and One Novel Mutation Detection of 6-pyruvoyl Tetrahydropterin Synthase Gene in Children with Tetrahydrobiopterin Deficiency [J]. Acta Academiae Medicinae Sinica, 2008, 30(2): 170-174.
[15]	HU Zheng-mao, XIE Zhi-guo, WU Ling-qian, LIANG De-sheng, ZHU Hai-yan, PAN Qian, LONG Zhi-gao, DAI He-ping, XIA Jia-hui, XIA Kun. Mapping of Pathogenic Genes in a Pedigree with Autosomal Dominant Ichthyosis Vulgaris [J]. Acta Academiae Medicinae Sinica, 2007, 29(3): 302-306.